The Lynx Group
Cholangiocarcinoma News

Final Results from ClarIDHy: Ivosidenib Extends Survival in Patients with Cholangiocarcinoma and IDH1 Mutation

March 2021, Vol 2, No 1

Final results from the phase 3 clinical trial ClarIDHy showed that ivosidenib (Tibsovo), a first-in-class oral inhibitor of isocitrate dehydrogenase 1 (IDH1) mutation, prolonged the median overall survival (OS) in patients with previously treated advanced cholangiocarcinoma (CCA) and IDH1 mutation. Although this improvement did not reach statistical significance, after adjusting for crossovers from the placebo to the ivosidenib group, the difference in median OS was statistically significant.

These results were presented at the 2021 ASCO Gastrointestinal Cancers Symposium by Andrew X. Zhu, MD, PhD, Director, Liver Cancer Research, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, and Director, Jiahui International Cancer Center, Jiahui Health, Shanghai, China.

The results showed an improvement in median OS of approximately 3 months with ivosidenib compared with placebo (hazard ratio [HR], 0.79; P = .093). The OS was a secondary end point of ClarIDHy.

The primary end point, reported previously, was improvement in progression-free survival (PFS). The median PFS was 2.7 months in patients assigned to ivosidenib compared with 1.4 months in patients who received placebo (HR, 0.37; P <.0001). The 6-month and 12-month PFS rates in the ivosidenib arm were 32% and 22%, respectively, and were not estimable in the placebo arm.

“The ClarIDHy study represents the first phase 3 study of a targeted, oral therapeutic with a noncytotoxic mechanism of action in advanced IDH1-mutated cholangiocarcinoma,” said Dr Zhu.

Effective treatment options for CCA are limited, he said. “IDH mutations occur in up to 20% of intrahepatic CCA, and lead to production of D-2-hydroxyglutarate, which promotes oncogenesis,” Dr Zhu emphasized.

New Drug Application

Based on these results, on March 1, 2021, a New Drug Application for ivosidenib was submitted to the FDA for the treatment of patients with CCA and IDH1 mutation. If approved, ivosidenib will be the first drug to receive approval for patients with CCA and IDH1 mutation.

ClarIDHy Study Details

ClarIDHy included 187 patients with unresectable or metastatic CCA and IDH1 mutation, as determined based on central testing and measurable disease. All the patients received 1 or 2 previous lines of therapy. The patients were randomized in a 2:1 ratio to ivosidenib 500 mg once daily or to placebo in continuous 28-day schedules. Crossover from the placebo arm to the ivosidenib arm was allowed at radiographic disease progression.

At baseline, 47.6% of the patients in the ivosidenib arm and 45.9% of the patients in the placebo arm had received 2 previous lines of treatment. More than 66% of the patients in both arms had an IDH1 R132C mutation and more than 90% of the patients in each arm had metastatic CCA, “highlighting the advanced setting of this population,” said Dr Zhu. The majority of the patients—89.7% in the ivosidenib arm and 95.1% in the placebo arm—had intrahepatic CCA.

In the final OS analysis, the median OS was 10.3 months in the ivosidenib arm versus 7.5 months in the placebo arm (HR, 0.79; P = .093). The study had a high level of crossover, with 43 of the 61 (70.5%) patients randomized to placebo crossing over to ivosidenib at radiographic disease progression.

When using the prespecified rank-preserving structural failure time model to adjust the OS for the crossovers, the adjusted median OS shrank to 5.1 months among those initially assigned to placebo, after which the OS advantage with ivosidenib became statistically significant (HR, 0.49; P <.0001).

The median duration of treatment in the ivosidenib arm was 2.8 months versus a median duration of treatment of 1.6 months with placebo. A total of 25 patients continued to receive ivosidenib for at least 1 year, including 6 patients who crossed over from placebo. In all, 30% (N = 18) of patients randomized to placebo did not cross over to ivosidenib, mostly because of death (N = 12).

Safety Profile

Grade 3 or 4 treatment-emergent adverse events were reported in 53% of the ivosidenib arm and 37.3% of the placebo group. The most common grade 3 adverse events were ascites, anemia, and an increase in the level of blood bilirubin. Adverse events leading to discontinuation were 8.5% in the placebo group versus 6.6% in the ivosidenib group. No treatment-related deaths occurred with the study drug.

Placebo recipients had significant declines in physical functioning and pain domains on health-related quality-of-life scales compared with those assigned to ivosidenib, at cycle 2 of treatment.

Related Items

Hot Topics in Cholangiocarcinoma and Biliary Tract Cancers: ASCO Highlights
September/October 2021, Vol 2, No 3
At the CCA Summit during the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO), Mitesh J. Borad, MD, Associate Professor of Medicine, Mayo Clinic, Phoenix, AZ, reviewed some of the key topics presented at ASCO 2021 related to cholangiocarcinoma (CCA) and other biliary tract cancers. Before turning to the specific presentations, Dr Borad welcomed the May 28, 2021, FDA approval of infigratinib (Truseltiq) for patients with advanced or metastatic CCA and FGFR2 fusions or rearrangements. Infigratinib follows pemigatinib (Pemazyre) as the second targeted therapy now available for this patient population.
CCA Summit Live from ASCO 2021
By Mitesh J. Borad, MD
On June 8, 2021, Dr Mitesh Borad, Associate Professor of Medicine at the Mayo Clinic in Phoenix, AZ, and a member of the Cholangiocarcinoma Summit Program Steering Committee, presented the top 15 abstracts on the management of cholangiocarcinoma and biliary tract cancer at ASCO 2021.
The Latest Research in Biliary Tract Cancers Presented at ASCO GI 2021
March 2021, Vol 2, No 1
At the CCA Summit held during the 2021 ASCO Gastrointestinal (GI) Cancers Symposium, Rachna T. Shroff, MD, MS, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, Tucson, discussed 15 clinical trials that were presented at the ASCO GI Cancers Symposium on cholangiocarcinoma (CCA) and hepatobiliary diseases. She highlighted key advances related to chemotherapy, targeted therapies, and biomarkers in the management of biliary tract cancers, including CCA.
Key Cholangiocarcinoma Abstracts Presented at ASCO GI 2021
By Rachna T. Shroff, MD, MS
Rachna Shroff, MD, from the University of Arizona Cancer Center, presents her insights into important new data in cholangiocarcinoma from ASCO GI 2021. New evidence is being presented on FGFR inhibitors, targeted therapies, chemotherapy in second-line, combination therapy, immunotherapy, and more.
Hot Topics on Cholangiocarcinoma and Biliary Tract Cancer Presented at ASCO 2020
By Milind M. Javle, MD
August 2020, Vol 1, No 1
Several hot topics were presented at the recent ASCO 2020 annual meeting about cholangiocarcinoma (CCA), which I would briefly discuss here. First, it was very exciting to see 3 important studies regarding immunotherapy for CCA, which may represent a step forward in the development of CCA therapies.
Assessing the Safety, Efficacy, and Biomarkers of Durvalumab in Chemotherapy-Naïve Patients with Advanced Biliary Tract Cancer
August 2020, Vol 1, No 1
Immunotherapies have shown early promising efficacy in some patients with biliary tract cancer. Investigators evaluated the benefit of durvalumab (Imfinzi), a PD-L1 inhibitor, with or without tremelimumab, a CTLA-4 inhibitor, plus chemotherapy with gemcitabine and cisplatin as a first-line treatment for Korean patients with biliary tract cancer. The researchers also performed an extensive biomarker analysis.
Combination Immunotherapy with Ipilimumab and Nivolumab Shows Activity in Patients with Advanced Biliary Tract Cancer
August 2020, Vol 1, No 1
The combination of a CTLA-4 inhibitor and a PD-1 inhibitor with ipilimumab (Yervoy) and nivolumab (Opdivo) has demonstrated superior efficacy compared with single-agent anti–PD-1 therapy in a previous study of patients with advanced melanoma and renal-cell carcinoma.
Nivolumab with Chemotherapy or with Ipilimumab as First-Line Therapy for Patients with Advanced Unresectable Biliary Tract Cancer
August 2020, Vol 1, No 1
Arandomized, phase 2 multi-institutional study compared the role of combination immunotherapy with nivolumab (Opdivo) plus ipilimumab (Yervoy) versus nivolumab plus chemotherapy with gemcitabine and cisplatin in the first-line treatment of patients with advanced biliary tract cancer.
Retrospective Analysis of Post–Second-Line Chemotherapy Outcomes in Patients with Advanced or Metastatic CCA and FGFR2 Fusions
August 2020, Vol 1, No 1
Cholangiocarcinoma (CCA) is the most common biliary tract malignancy, with an estimated incidence of 8000 to 10,000 patients annually in the United States. Chemotherapy is the most common second-line treatment with response rates of <10% and median progression-free survival (PFS) of approximately 3 to 4 months, including FOLFOX in the ABC-06 trial. Fibroblast growth factor receptor (FGFR) 2 fusions occur in 13% to 17% of patients with CCA, and multiple targeted agents are in development for patients with FGFR2 fusions. To date, the outcome of patients with CCA and FGFR2 fusions who receive standard second-line chemotherapy is unknown.
Natural History of Cholangiocarcinoma with FGFR Alterations
August 2020, Vol 1, No 1
Genetic alterations in the fibroblast growth factor receptor (FGFR) pathway are emerging as promising therapeutic targets in patients with cholangiocarcinoma (CCA). A retrospective chart review, led by Lipika Goyal, MD, MPhil, Medical Oncologist, Tucker Gosnell Center for Gastrointestinal Cancers, Massachusetts General Hospital, Boston, was performed in patients with CCA who had an FGFR alteration found by tumor molecular profiling as part of routine care.1 Dr Goyal presented this study at the 2020 ASCO annual meeting.

Subscribe to CCA News

Stay up to date with personalized medicine by subscribing to receive the free CCA News print publication or weekly e‑Newsletter.

I'd like to receive: